Phenytoin is a frequently used drug treatment for epilepsy. Genetic polymorphisms in the metabolism of phenytoin, particularly CYP2C9, are strongly associated with increased plasma concentrations a...
1 June 2021 in Journal of Investigative Dermatology
Cisplatin-induced ototoxicity remains a significant concern in pediatric cancer treatment due to its permanent impact on quality of life. Previously, genetic association analyses have been performed to detect genetic variants associated with this adverse reaction. In this study, a combination of interpretable neural networks and Generative Adversarial Networks (GANs) was employed to identify genetic markers associated with cisplatin-induced ototoxicity. The applied method, BRI-Net, incorporates biological domain knowledge to define the network structure and employs adversarial training to learn an unbiased representation of the data, which is robust to known confounders. Leveraging genomic data from a cohort of 362 cisplatin-treated pediatric cancer patients recruited by the CPNDS (Canadian Pharmacogenomics Network for Drug Safety), this model revealed two statistically significant single nucleotide polymorphisms to be associated with cisplatin-induced ototoxicity. Two markers within the CERS6 (rs13022792, p-value: 3 × 10-4) and TLR4 (rs10759932, p-value: 7 × 10-4) genes were associated with this cisplatin-induced adverse reaction. CERS6, a ceramide synthase, contributes to elevated ceramide levels, a known initiator of apoptotic signals in mouse models of inner ear hair cells. TLR4, a pattern-recognition protein, initiates inflammation in response to cisplatin, and reduced TLR4 expression has been shown in murine hair cells to confer protection from ototoxicity. Overall, these findings provide a foundation for understanding the genetic landscape of cisplatin-induced ototoxicity, with implications for improving patient care and treatment outcomes.
Background: L‐asparaginase is essential in treating pediatric acute lymphoblastic leukemia (ALL) but is limited by hypersensitivity reactions in up to 70% of patients, leading to severe, dose‐limiting complications and compromised event‐free survival.Procedure: This study conducted a genome‐wide association study (GWAS) in a discovery cohort of 221 pediatric cancer patients who experienced l‐asparaginase–induced hypersensitivity reactions (≥CTCAE grade 2) and 705 controls without hypersensitivity despite equivalent exposure. Results were replicated in an independent cohort of 41 cases and 139 controls.Results: Significant associations were identified between hypersensitivity and four genes crucial for amino acid stress response: CYP1B1 (rs59569490; odds ratio [OR] = 8.5; 95% confidence interval [CI], 3.9–18.5; p = 1.5 × 10−10), SEC16B (rs115461320; OR = 4.2; 95% CI, 2.5–7.9; p = 1.2 × 10−6), OPLAH (rs11993268; OR = 4.8; 95% CI, 2.4–9.9; p = 2.0 × 10−6), and SORCS2 (rs11940340; OR = 6.7; 95% CI, 2.8–15.7; p = 5.7 × 10−7). Variants in SEC16B, OPLAH, and SORCS2 remained significant in the analysis of the replication cohort (p < 0.05). Patients who carried risk alleles in two or more of these genes experienced an 86.4% increased incidence of hypersensitivity reactions in the discovery cohort (OR = 25.2; 95% CI, 7.4–86.2; p = 1.0 × 10−10), which was replicated in the independent cohort with a 100% incidence in carriers (p = 0.04).Conclusions: The cumulative incidence of these large effect variants highlights their significance for the identification of patients at high risk of l‐asparaginase–induced hypersensitivity. Successfully identifying patients at increased risk of hypersensitivity reactions can inform personalized treatment strategies and limit these harmful dose‐limiting reactions in pediatric ALL.
Background: L‐asparaginase is a critical component in treatment protocols for pediatric acute lymphoblastic leukemia. Acute pancreatitis reactions can necessitate delays and, in some cases, discontinuation of L‐asparaginase, which compromises outcomes. Procedure: Genome‐wide analyses were conducted to identify significant associations between single‐nucleotide polymorphisms and risk for L‐asparaginase‐induced pancreatitis in 1086 pediatric patients treated on acute lymphoblastic leukemia treatment protocols. Patients were randomly split 75/25 into independent Discovery ( n = 824) and Replication ( n = 262) cohorts. Cases experienced Common Terminology Criteria for Adverse Events v5.0 Grades 3–4 acute pancreatitis reactions due to L‐asparaginase treatment. Controls received L‐asparaginase but did not develop acute pancreatitis. Results: A significant association was observed between the rs149210846 variant and L‐asparaginase‐induced pancreatitis (odds ratio [OR] = 8.9; 95% confidence interval [CI]: 3.6–22.3; p = 1.8 × 10 −8 ) and was confirmed in the replication analysis (OR = 6.2; 95% CI: 1.1–35.0; p = 0.02). Carriers had 5.9‐fold (95% CI: 1.9–16.3; p = 0.002) and 7.7‐fold (95% CI: 1.3–29.3; p = 0.01) increased risk of severe Grade 3 and Grade 4 acute pancreatitis reactions, respectively, relative to non‐carriers. Moreover, patients of Admixed‐American (OR = 8.8; 95% CI: 2.4–34.6; p = 1.45 × 10 −3 ) and Asian (OR = 10.0; 95% CI: 1.9–53.6; p = 8.06 × 10 −3 ) genetic ancestries were at significantly higher risk. Conclusions: These findings will allow clinicians to proactively conduct stricter monitoring of patients at higher risk for L‐asparaginase‐induced pancreatitis and inform future development of protective agents that can be used concomitantly to mitigate their risk.
As a first-line therapy for hyperuricemia, allopurinol is a recognized cause of severe drug reactions. While screening for the HLA-B*58:01 risk allele is recommended in certain Asian populations, individuals from other ancestries may also possess susceptibility alleles. A 68-year-old Filipino woman developed Drug Reaction with Eosinophilia and Systemic Symptoms following reinitiation of allopurinol, despite a history of long-term tolerance. Approximately 3 months after reinitiation, she presented with a progressive pruritic eruption, eosinophilia, and acute kidney injury. Discontinuing allopurinol and starting prednisone improved renal function and resolved eosinophilia. Human leukocyte antigen genotyping identified both HLA-B*58:01 and HLA-A*33:03 , alleles associated with allopurinol-induced severe cutaneous adverse reactions and reported in several Asian populations, including Filipinos. The patient completed a prednisone taper with full resolution of symptoms. This case highlights the need to consider pharmacogenetic risk factors beyond traditionally targeted ethnic groups and demonstrates that this reaction may develop after reinitiation with dose escalation of allopurinol, despite earlier tolerance.